Methotrexate (MTX) is a well-known immunomodulator in the treatment of inflammatory bowel disease (IBD) and often combined with biological agents. The ideal MTX dose for combination therapy has not been determined. Our aim is to investigate the effect of varying doses of MTX when used with anti-TNF agents in IBD on efficacy and safety outcomes.